BIOMARCATORI 1
19
1
Prolonged low-rate nerve stimulation during regional ischemia: a potential neurophysiological biomarker in McArdle disease
2
Systematic assessment of square wave jerks in progressive supranuclear palsy: a video-oculographic study
3
Longitudinal changes in cerebrospinal fluid alpha-synuclein RT-QuIC outcomes during the preclinical to clinical stages of neuronal synuclein disease
4
A real-life study to assess K-index diagnostic and prognostic role in early phases of Multiple Sclerosis (MS)
5
Cerebrospinal fluid NPTX2 and metabolic correlates of delayed recall in MCI-AD: insights from FDG-PET voxel-wise analysis
6
Visinin-like protein-1 in cerebrospinal fluid as a biomarker of neuronal damage in dementia and mild cognitive impairment due to Alzheimer Disease: a cross-sectional study
7
Rituximab in refractory myasthenia gravis: 5 year single center follow up
8
Assessment of cardiovascular risk factors and impact on prognosis in multiple sclerosis: a single center experience
9
Oral curcumin for Alzheimer's disease: impact on CSF neurochemical profile
10
Correlation between markers of dysregulated mitochondrial dynamics and synaptic dysfunction in patients with Alzheimer Disease
11
Pupillary light reflex in the early stages of alpha-synucleinopathies
12
Assessment of neurodegeneration markers in olfactory neurons of patients with post-Covid 19 olfactory dysfunction
13
Kidney function and Alzheimer's disease: impact on plasma biomarkers and correction factors
14
The identification of prodromal Dementia with Lewy Bodies by skin biopsy among patients with recent-onset dementia
15
Determinants driving evolution of newly formed MS lesion into chronic active, chronic demyelinated and remyelinated lesions
16
Neurofilament light chain as clinical plasma biomarker of Charcot-Marie-Tooth disease
17
Understanding the interplay between multiple sclerosis patterns and ovarian reserve
18
Sex-Related Differences in Inflammatory Pathways in Schizophrenia Spectrum Disorders
19
Serum miRNA signature in neurofibromatosis type 1: emerging biomarkers and clinical implications
BIOMARCATORI 2
19
340
Role of specific microRNAs in cluster headache: correlation with disease phenotype and neuropeptide levels
341
Stage-dependent phosphoproteomic profile of Parkinson's disease peripheral immune cells
342
Does cerebrospinal fluid neurofilament light chain correlate with psychiatric symptoms severity in multiple sclerosis?
343
Oculomotor features in SCA27B patients
344
Biomarkers of Neurodegeneration in iNPH, LOVA, and other neurodegenerative diseases: a pilot study.
345
Gastrointestinal dysfunction accounts for a specific clinical-biological profile in Parkinson's disease
346
Microbiota-derived metabolome: towards a non-invasive biomarker of multiple sclerosis
347
Linking Mitochondrial Dysfunction with Glial and Neuroaxonal degeneration in Creutzfeldt-Jakob Disease
348
Control of core temperature in major orthopedic surgery and traumatology in old patinets with delirium using donepezil
349
Control of core temperature in major orthopedic surgery and traumatology in old patinets with delirium and valutation Mini Mental test.
350
Plasma pTAU levels can distinguish cognitively unimpaired patients with PD from patients with HC and patients with PDD, DLB and AD.
352
Ofatumumab Reduces Clinical and Radiological Activity in People with Recently Diagnosed Treatment-naive Relapsing Multiple Sclerosis Irrespective of Baseline Serum Neurofilament Light Chain Levels
353
Prognostic Value of Serum Neurofilament Light Chain for Disease Activity in Patients With Relapsing Multiple Sclerosis: Results From Subgroup Analysis Based on Body Mass Index and Age from the Phase 3 ASCLEPIOS I/II Trials
354
Prognostic Value of On-Treatment Serum Neurofilament Light Chain for New or Enlarging T2 Lesions in People With Relapsing Multiple Sclerosis: Pooled Analysis of the ASCLEPIOS I/II Trials
355
CSF and amyloid PET concordance in amyloid pathology detection: a comparison of the two methods
356
Blood-Brain Barrier alterations as possible biomarkers of Depressive symptoms in Alzheimer's Dementia Patients
357
The relationship between Synaptic dysfunction and Neuronal, Glial and Inflammatory alterations in Alzheimer's disease
358
Establishment of normal reference values for serum neurofilament light based on apparently healthy subjects aged 18Cb,b 90 years."
359
Performance and concordance of plasma versus CSF biomarkers of Alzheimer's Disease: a single center Memory Clinic cohort"
BIOMARCATORI 3
19
675
Baseline Serum Neurofilament Light Chain Levels Predict Future Disease Activity Irrespective of Race/Ethnicity: Results From the Phase 3 ASCLEPIOS I/II Trials
676
Role of blood p-tau isoforms (181, 217, 231) in predicting the progression from MCI to dementia due to Alzheimer's disease: a review and metanalysis
677
Patients affected by Alzheimer's disease with different Rate of Progression showed differences in CSF biomarkers related to Neurodegeneration and Synaptic disfunction: a preliminary study."
678
Blood-based biomarkers of oxidative stress to predict post-operative cognitive impairment in patients undergoing coronary artery bypass grafting
679
Cerebrospinal fluid interleukin-6 as a potential biomarker in CNS neuroinflammatory diseases: a real world analysis.
680
Real-world performance of serum biomarkers for the detection of amyloid brain pathology
681
Neurofilament Light Chain and AlzheimerCb,b"s Pathology in Elderly Patients with Multiple Sclerosis"
682
Neuronal and glial biomarkers in a cohort affected by Lewy Body Dementia with and without GBA1 mutations: a multicentric deep-phenotyping biological study
683
Adding mindfulness practice to treatment as usual in patients with CM-MOH: an analysis of inflammatory pattern
684
Plasmatic ACB242/40 ratio and p-tau181 in A+/T+ patients: diagnostic performance in a real-world setting
685
Correlations between CSF biomarkers of AlzheimerCb,b"s disease and neuropsychological tests in a cohort of Parkinson disease patients"
686
Circulating X chromosome inactivation and Xist from a cohort of female carriers of Fabry Disease
687
Preliminary analysis of Tissue Transglutaminase 2 expression in peripheral blood mononuclear cells in patients with Radiologically Isolated Syndrome
688
Impact of Augmentative Alternative Communication on Healthcare Providers satisfaction: Enhancing Communication with Aphasic Patients.
689
THE POTENTIAL ROLE OF ALFA-2 MACROGLOBULINE AND S100B PROTEIN AS A PREDICTORS OF FUNCTIONAL OUTCOME IN STROKE PATIENTS. PRELIMINARY RESULTS FROM THE NIMBLE STUDY.
690
Beware of the tick! A case of Borrelia-induced CNS vasculitis presenting with recurrent posterior circulation strokes
691
When the heart speaks first: a 30 years history of pseudo-drug resistant epilepsy.
692
SOD1-ALS PATIENTS IN TOFERSEN: LONGITUDINAL EVALUATION OF CLINICAL AND BIOLOGICAL VARIABLES
694
Diagnostià iomarkers in patients with mild traumatià rain injury. BIO-BRAIN: rationale and study design.
brain health e prevenzione/ neurologia digitale/ neuroepidemiologia
13
929
Heat Stress and Neurological Damage: Analysis of Neuro-Glial Damage Biomarkers
930
Enhancing Cognitive and Brain Reserve: Exploring the Impact of Foreign Language Learning on the Aging Brain
931
Assessment of Nutritional Status in patients with Cognitive Impairment: a pilot study
932
AN OVERALL PICTURE OF OUTPATIENTS NEUROLOGY SERVICES IN THE LATIUM REGION, ITALY
933
A multicenter study in Sicily, Southern Italy on immune mediated syndromes associated to onconeural antibodies
934
Visual Pareidolia in non-demented patients of a Stroke Unit
935
Clinical evolution and survival of chronic patients with Disorders of Consciousness: a retrospective study
936
Guillain-BarrCB) Syndrome during the COVID-19 pandemic in Italy: self-controlled case series- SCOVANE study
938
The EU project "STRATIF-AIC"
939
The Lombardia Region PERLA project: towards a new diagnostic and therapeutic pathway for patients with chronic headache disorders
940
Feasibility and effectiveness of a mindfulness program delivered by web to patients during hospitalization and caregivers: a pilot study (The KIMPO Project)
941
Cooperation protocol for social and health care integration in Milan area. Districts 7-6-5 experience.
942
Wellbeing at the work place and behind: Feasibility and effectiveness of a mindfulness program delivered by web to nurses in an Italian neurological department: a pilot study
CEFALEE E DOLORE 1
22
20
Influence of triptans use on anti-CGRP mAbs response: a prospective cohort study
21
Gender differences in the expression of central sensitization symptoms in migraine: an observational study in a tertiary headache center
22
ENDOVASCULAR VENOUS SINUS STENTING: A VALID THERAPEUTIC OPTION IN REFRACTORY IDIOPHATIC INTRACRANIAL HYPERTENSION.
23
Molecular-enriched functional connectivity fingerprint of the serotonin system in medication overuse headache patients
24
COMPARISON OF EFFECTIVENESS AND SAFETY OF MONOCLONAL ANTIBODIES TARGETING CGRP FOR MIGRAINE PREVENTION AND AGE-RELATED SUB-GROUPS ANALYSIS: A 12-MONTHS, MULTICENTER, PROSPECTIVE, REAL-LIFE STUDY
25
LOST IN TRANSITION: FACTORS ASSOCIATED WITH EFFECTIVE TRANSITION FROM PEDIATRIC TO ADULT HEADACHE CARE
27
Efficacy of galcanezumab in PRRT2-associated Familial Hemiplegic Migraine: a case series.
28
Unveiling the demographic, social, and clinical characteristics of migraine in Italy: Insights from the Nationwide, Prospective, Italian Migraine Registry (I-GRAINE)
29
Gut microbiota ecosystem in pediatric migraine. How are dysbiosis, inflammation and intestinal metabolites involved?
30
A head to head cohort study on the effiacy and safety of Indomethacin and Ibuprofen for the acute treatment of migraine
31
Early effect of OnabotulinumtoxinA on EEG-based functional connectivity in patients with chronic migraine
32
Multi-parametric efficacy assessment of Eptinezumab in patients with chronic migraine and medication overuse headache: early results from a third level headache center.
33
High prevalence of fatigue in migraine patients in comparison with other chronic neurological diseases
34
Functional connectivity alterations in medication overuse headache
35
ANALYSIS OF FACTORS INFLUENCING THE MONOCLONAL ANTIBODIES AGAINST CGRP PRESCRIPTION IN A COHORT OF VERY YOUNG ADULTS WITH MIGRAINE.
38
Exploring Atypical Spontaneous Intracranial Hypotension: a case of Myasthenia Gravis with Brain Sagging
39
Brain resting state networks in episodic cluster headache: cerebral connectivity analysis with HD-EEG
40
Sustained Response to Atogepant in Individuals With Episodic Migraine and Prior Inadequate Response to Preventive Treatment and in Individuals With Chronic Migraine: Post hoc analyses From ELEVATE and PROGRESS
41
Real-world Switching Rates of Atogepant Are Lower Than CGRP Monoclonal Antibodies (mAbs) in Patients With Migraine Using Claims Database
42
Inflammatory profile and monocytes differentiation in migraine: association with disease severity
43
Restarting migraine preventive treatment with CGRP antibodies after drug holiday: Insights from the Mondino Tertiary Care Center real-world experience
44
Exploring Gender Disparities in the Effects of Long-Term Botulinum Toxin A Treatment for Chronic Migraine
CEFALEE E DOLORE 2
22
360
In a population of young stroke patients, the characteristics of migraine with aura can predict the likelihood that the stroke is related to the presence of a PFO?
361
Impact of Atogepant on Patient Functioning Among Participants With Episodic Migraine: Migraine-Specific Quality of Life Questionnaire v2.1 Item-Level Analysis
362
REVERSIBLE CEREBRAL VASOCONSTRICTION SYNDROME: A RARE CAUSE OF MIGRAINE WITH AURA
363
Evaluation of Crystal-Clear Days in Migraine Patients Receiving CGRP Monoclonal Antibodies
364
Is there still a place for detoxification strategies in migraine therapeutic scenario?
365
Head-to-head observational cohort study on the effectiveness and tolerability of subcutaneous monoclonal antibodies acting on CGRP pathway in patients with high frequency episodic migraine and chronic migraine
366
Morphometric Similarity Networks in paediatric migraine without aura: unravelling the role of gender
367
Alexithymia increases the risk of chronification in women with migraine; preliminary results
368
Recurrence of migraine after discontinuation of Anti-CGRP monoclonal antibodies: predictive clinical factors
369
Daily and night functioning improvement in pharmacoresistant migraine patients just after 6 months treatment with Anti CGRP/R mAbs
370
Bipolar spectrum disorders and cyclothymia are associated with Medication overuse
371
COVID 19 RELATED HEADACHE AND LONG COVID HEADACHE: SINGLE CENTER EXPERIENCE
372
Effectiveness and safety of using anti-CGRP monoclonal antibodies in migraine patients with a comorbidity disorder
373
Cervical meningioma underlying facial episodic paresthesia, tinnitus and vertigo
374
Effect of anti-CGRP monoclonal antibodies on anxiety and mood disorders in migraineurs
375
Evaluation of Eptinezumab effectiveness and tolerability: real life single-centre experience
376
Evaluation of migraine related cognitive symptoms in patients with high frequency episodic and chronic migraine
377
Advancing Globally Neurological Education in the Headache Field
378
IS THE 15-DAY THRESHOLD IN THE DEFINITION OF MIGRAINE WORSENING ASSOCIATED TO MEDICATION OVERUSE REASONABLE?
379
Results from the 2nd Italian interim analysis of the PEARL study: participants' quality of life over 12 months with fremanezumab treatment
382
Beyond Idiopathic Intracranial Hypertension: A Case of Hidden Dural Arteriovenous Fistula
383
A STRANGE CASE OF HEADACHE IN THE ELDERLY
CEFALEE E DOLORE 3
20
695
Eptinezumab treatment in patients with previous anti-CGRP (R) monoclonal antibodies therapy: a retrospective study of real-world clinical evidence of efficacy
696
A series of unfortunate events: two rare neurological complications of a rare tumor at carotid bifurcation
697
ANCA-associated hypertrophic pachymeningitis: a rare cause of headache and progressive cranial neuropathies
698
Hemiplegic migraine as presenting symptom of Evans syndrome: a case report
699
Recurrent painful ophthalmoplegic neuropathy: a high frequency case with adulthood onset.
700
RECURRENT DIPLOPIA AS ISOLATED SYMPTOM OF ATYPICAL SPONTANEOUS INTRACRANIAL HYPOTENSION
701
An Unusual Presentation of Giant Cell Arteritis
702
A Case of Glossopharyngeal Neuralgia Successfully Treated with Amitriptyline and Gabapentin
703
Anti-CGRP mAbs in a 92-year-old patient: A CASE REPORT
704
Acute Unilateral Sixth Cranial Nerve Palsy and Headache as Initial Manifestations of Carcinomatous Meningitis
707
An unusual occipital-temporal headache in a 17 years old boy: the value of somatosensory evoked potentials (SSEP)
708
Persistent Idiopathic Facial Pain. A challenging diagnostic entity: clinical experience from a Neuroalgology Department
709
Cognitive and Mood Evaluation in Trigeminal Neuralgia Patients Pre- and Post-Gamma Knife Treatment
710
Dr. Rita Formisano
711
Vascular Compression in Trigeminal Neuralgia Discloses Trigeminal Root Somatotopic Organization
712
Diagnostic accuracy of quantitative sensory testing for the diagnosis of small fibre neuropathy
715
Gender disparities in response to treatment with subcutaneous injections of Botulinum toxin type A in chronic neuropathic pain.
716
Gabapentinoids use and abuse in Neuropathic Pain Unit
717
Presenting a protocol for using abobotulinumtoxinA to treat neuropathic pain in carpal tunnel syndrome: A multicenter, randomized, double-Blind, placebo-controlled Study (INjECT Study).
718
Long-Term Safety, Tolerability, and Efficacy of Atogepant for the Preventive Treatment of Migraine: Interim Analysis of a Phase 3, Multicenter, Open-Label, 156-Week Long-Term Safety Extension Study
DEMENZA E INVECCHIAMENTO 1
23
85
Discriminative Accuracy of Plasma pTau-217 Assessed by Automated Lumipulse G600II Across CSF Biomarker Profiles in AlzheimerCb,b"s Disease"
86
Peripapillary retinal nerve fiber layer thickness in MCI and dementia
87
Risk of dysphagia in primary progressive aphasia: demographic, clinical, behavioural and neuroanatomical features
88
Sentence comprehension deficits in Italian and English nfvPPA: A cross-linguistic perspective.
89
An Italian scale for the assessment of motor speech disorders in patients with neurodegenerative diseases
90
Amy-PET features of regional amyloid deposition and hypoperfusion in probable CAA: a preliminary study
91
Neuropsychological tests as predictors of amyloid-PET status in a heterogeneous cohort of MCI and mild dementia patients
92
Gender differences in Cognitive Reserve in Subjective Cognitive Decline: a problem of belonging generation?
93
Brain functional connectivity changes and cortical neurotransmitter receptor distribution associated with psychotic symptoms in AlzheimerCb,b"s disease "
95
Brain hypometabolism and errors on the Clock Drawing Test predict conversion from Mild Cognitive Impairment to Alzheimer's dementia"
96
The role of neuroinflammation in Alzheime's disease: A systematic literature review."
97
Optimizing Early Detection of Cognitive Impairment: Evaluating Toolkits for Screening First-Time SCD Patients
99
Effects of lamotrigine to reduce emotional lability in AlzheimerCb,b"s disease and vascular dementia"
100
Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of oral semaglutide in patients with early Alzheimer's disease.
101
Anti-amyloid monoclonal antibodies and ARIA in Early AD: A case series with favorable outcomes
102
Informal and Formal Settings in Neuropsychological Evaluation in Moderate-Severe AlzheimerCb,b"s Disease"
103
Plasma phospho-Tau 181 as a predictor of emergency department use in cognitively impaired patients: preliminary results from an ongoing longitudinal study.
104
Normal pressure hydrocephalus does not matter: an Italian perspective
105
Prevalence of idiopathic normal pressure hydrocephalus in patients with fractures
106
Idiopathic Normal Pressure Hydrocephalus: A Critical Analysis of Its Underrepresentation Across Italian Medical-scientific Societies in the last 5 years
107
Control of core temperature in major orthopedic surgery and traumatology in old patinets with delirium
108
Control of core temperature in major orthopedic surgery and traumatology in old patinets with delirium and valutation of pressure sores
109
Control of core temperature in major orthopedic surgery and traumatology in old patinets
DEMENZA E INVECCHIAMENTO 2
21
447
In 2024 iNPH is still a social and economic burden
448
Associations between Biomarkers of Amyloidopathy, Tauopathy, Neurodegeneration and Inflammation and Blood-Brain Barrier Dysfunction in Mild Cognitive Impairment due to Alzheimer's Disease
449
Young-onset dementia in Padova County: epidemiological and care-pathway study
451
The relationship between blood-based protein biomarkers and brain MRI in the Alzheimer's disease continuum: A systematic review"
453
Serum Neurofilaments as diagnostic biomarkers in late-onset frontal lobe syndrome: role in the differential diagnosis of FTD versus primary psychiatric diseases
454
Is there a causative role of intermediate C9orf72 expansion in frontotemporal dementia? A case series.
455
Evaluation of participant characteristics in clinical trials investigating amyloid- and tau-targeting monoclonal antibodies for Alzheimer's disease: a systematic review"
457
Combined intake of red wine and mocha coffee on cognition and mood in elderly patients with mild vascular cognitive impairment
458
Cerebrospinal fluid/serum albumin ratio (Q-Alb) in frontotemporal lobar degeneration syndromes
459
Validation and Convergent Validity of the Boston Cognitive Assessment (BOCA) in an Italian Population: A Comparative Study with the Montreal Cognitive Assessment (MoCA) in Alzheimer's Disease Spectrum.
460
The impact of comorbidities on dementia conversion: a principal component and cluster analysis
461
KOKEDAMA: A NEW JAPANESE GARDENING TECHNIQUE FOR ALZHEIMER DISEASE AND DEMENTIA
462
At the crossroads between Frontotemporal Dementia and AlzheimerCb,b"s Disease: a case report"
463
Atypical presentations of Lewy bodies disease misdiagnosed with limbic encephalitis or epileptic seizures: a case series with EEG and FDG-PET/MRI findings
464
Inflammatory cerebral amyloid angiopathy with focal leptomeningeal involvement: multimodal imaging findings
465
Epidemiological study on potential protective factors for dementia in a small Italian village
466
Acute neuropsychiatric deficits with hypermetabolism of the bilateral amygdala: the dilemma between autoimmune encephalitis and Lewy body disease.
467
Familial Creutzfeldt-Jakob disease. Description of a new case.
468
Acute Wernicke's encephalopathy mimicking stroke in esophageal cancer receving chemioterapy
469
Aspecific visual field defects as the first presentation of dementia: a case of posterior cortical atrophy
470
Frontal variant of AlzheimerCb,b"s disease: a challenging diagnosis"
DISORDINI DEL MOVIMENTO 1
21
252
A new wearable device based on inertial sensors to predict the DAT-SPECT result in patients with rest tremor: implications for routine clinical practice
253
Acute and long-term effects of Deep Brain Stimulation on cortico-cortical functional connectivity in ParkinsonCb,b"s disease: a high-density EEG study"
255
Brain hypometabolism and clinical features of GBA individuals
256
Conventional investigations in patients with Functional Motor Disorders
257
GLP-1 receptor agonist: a new disease-modifying therapy in Parkinson's disease? A systematic review and meta-analysis
258
Longitudinal assessment of blepharospasm severity in patients with long disease duration
259
Characterization of lower urinary tract symptoms in Parkinson's disease Clinical Subtypes
260
Analysing the bradykinesia features combination in people with ParkinsonCb,b"s disease and elderly healthy individuals"
261
Disentangling Bradykinesia and Rigidity in Parkinson's Disease: Evidence from Short- and Long-Term Subthalamic Nucleus Deep Brain Stimulation
262
Periodic Leg Movements during Sleep Associated with REM Sleep Behavior Disorder: A Machine Learning Study
263
Comparison of tolerability and efficacy of different add-on therapies in fluctuating Parkinson's disease patients
264
Reliability of neurophysiological and cerebral tremor features in Parkinson's disease
265
Retinal alterations in patients with ParkinsonCb,b"s Disease and visual hallucinations."
266
Magnetic Resonance-guided Focused Ultrasound (MRgFUS) in patients with ParkinsonCb,b"s disease: motor effects beyond tremor "
267
Genotype-phenotype correlation in a genetic ParkinsonCb,b"s disease cohort: analysis of a single center experience"
268
Botulinum toxin modulates the thalamocortical network in patients with cervical dystonia
269
Movement disorders after basal ganglia ischemic lesions following mechanical thrombectomy: an emerging clinical entity.
273
The influence of sex hormones on EEG-based functional connectivity in early-stage ParkinsonCb,b"s disease patients "
274
Rigidity in ParkinsonCb,b"s disease: the effect of L-dopa and activation maneuver on viscoelastic components"
275
Risk assessment is selectively biased by dopaminergic drugs in impulsive-compulsive parkinsonian patients
276
Diagnostic outcomes of Acute/Subacute Chorea: a retrospective analysis with a systematic literature review
DISORDINI DEL MOVIMENTO 2
23
277
Primary endpoints in randomized controlled trials evaluating Deep Brain Stimulation in Parkinson's disease
278
Investigating the effects of anodal transcranial direct current stimulation on the primary motor cortex in multiple system atrophy: a small pilot study.
280
Real-world experience of the safety of magnetic resonance imagingCb,b guided focused ultrasound (MRgFUS)-thalamotomy for essential tremor"
282
Phenotypic comparison between Combined Dystonia Parkinsonism and Isolated Idiopathic Dystonia
283
Investigating cerebral network changes in cervical dystonia using transcranial magnetic stimulation and electroencephalography
284
Continuous gait monitoring of Parkinson's disease patients during STN DBS under chronic sensing: a pilot study"
285
L-Dopa/Carbidopa Intestinal Gel in Advanced Parkinson's Disease: Long-term Monitoring through Wearable Sensors "
286
Safinamide introduction in ParkinsonCb,b"s Disease: a potential to spare antiparkinsonian therapy over time"
287
Physical activity and neurotrophic factors as potential drivers of neuroplasticity in ParkinsonCb,b"s Disease: A systematic review and meta-analysis."
288
Effects of GBA mutations in patients with Parkinson's disease and Levodopa-carbidopa intestinal gel: a nation-wide multicentre study
289
Motor and nonmotor functional connectivity predicts treatmentCb,brelated motor complications in early ParkinsonC"b,b"s disease patients"
290
Testing Machine Learning Algorithms to Evaluate L-dopa Response and Cognitive Impairment in ParkinsonCb,b"s Disease by Motion Sensors and EEG Data"
291
Optimizing Deep Brain Stimulation Parameters in a GBA-related Parkinso's Disease Patient: a comparison of monopolar review, 3D-reconstructions and Beta-sensing"
292
Functional brain architecture is shaped by sex in drug naCB/ve Parknson's disease patients"
293
Handwriting in Parkinson s Disease: a study with artificial intelligence
294
Assessing ChatGPT ability to answer laypeople questions about Essential Tremor
295
Dynamic quantitative evaluation of axial postural abnormalities associated with Parkinson's disease: a pilot study.
296
The cerebellar cognitive affective syndrome in ET subtypes
297
Smell performances in patients with Bipolar Disorder and parkinsonian signs compared to Parkinson Disease and Healthy Subjects
298
THE WHISTLE-SMILE REFLEX IN PARKINSON'S DISEASE: A CROSS-SECTIONAL STUDY
299
Safinamide effect on sleep architecture of motor fluctuating ParkinsonCb,b"s disease patients: a polysomnographic rasagiline-controlled study"
300
The genetic landscape of Parkinson's Disease in an Italian cohort and the need for a standardized approach
301
Static postural control is affected even in mild Freezing of Gait in ParkinsonCb,b"s Disease"
DISORDINI DEL MOVIMENTO 3
25
596
Arm Swing Kinematics in Parkinson's Disease: Clinical Insights"
597
Body image appearance in Parkinson's disease patients on advanced therapies
598
Dysautonomia and cognitive impairment as clinical predictors of disease progression in patients with Parkinson's disease"
599
Transcranial alternating current stimulation of the cerebellum in cervical dystonia
600
RETINAL THICKNESS IN ESSENTIAL TREMOR PLUS (ET PLUS): CORRELATION WITH CLINICAL VARIABLES
601
Kinematic signature of rigidity during passive upper limb mobilization in patients with Parkinson's disease"
602
Neurophysiological and clinical effect of botulinum toxin in essential blepharospasm
603
Opicapone improves end-of-dose neuropsychiatric fluctuations in patients with Parkinson disease: a 6-month follow-up study
604
Management of PEG-J related complications in advanced Parkinson's disease patients: a monocentric experience
605
The role of pathology validation on the association between smoking and Parkinson's Disease
606
GALC variants in adult patients with neurodegenerative diseases: results from LysoLate study.
607
Role of CITIcoline as supportive therapy in PARKinson's disease: the CITIPARK trial.
609